**Evidence Table 5. Benefits (KQ 1 & 2)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Ahrens, 20021NA | NA | NR | PSS-SR (range: NR), Mean DifferencePretreatment G1: 16.89 (SD=10.49)G2: 19.36 (SD=10.12)Within group change:G1: -9.07 (calculated)G2: 1.02 (calculated)Between group change: -10.09 (calculated) ANOVA (1, 36)=19.44, p=0.0001IES (range: NR), Mean Difference Pretreatment G1: 35.52 (SD=11.80)G2: 33.42 (SD=8.70)Within group change:G1: -12.11 (calculated)G2: 2.08 (calculated)Between group change: -14.19 (calculated) ANOVA (1, 36)=20.49, p=0.0001 | BDI (range: NR), Mean differencePretreatment G1: 15.26 (SD=12.10)G2: 18.52 (SD=9.97)Within group change:G1: -8.38 (calculated)G2: -0.58 (calculated)Between group change (95% CI): -7.80 (calculated) ANOVA (1, 36)=17.95, p=0.02 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Berger, 20072NA | UPID-Severity (range: 0-68): Pretreatment G1: 25.6 (SD=12.3)G2: 23.5 (SD=11.2)Within group change at post-treatment:G1: -11.7 (calculated)G2: 0.4 (calculated)Between group change at post-treatment: -12.1 (calculated)Between group ANOVA: F=129.33, df=1,140, p<0.001Symptoms (range: 0-17):Pretreatment G1: 7.6 (SD=3.9)G2: 6.7 (SD=3.8)Within group change at post-treatment:G1: -3.7 (calculated)G2: 0.9 (calculated)Between group change at post-treatment: -4.6 (calculated)Between group ANOVA: F=132.62, df=1,140, p<0.001 | UPID-DiagnosisPretreatmentG1: 8.6% (calculated)G2: 6.9% (calculated)Within group change in proportion with PTSD at post-treatmentG1: -8.6% (calculated)G2: 0%Between group change in PTSD diagnosis proportion at post-treatment: -8.6% Significance not reported | NA | SCARED, Generalized Anxiety, MeanGeneralized anxiety (range: 8-24):Pretreatment G1: 12.5 (SD=2.9)G2: 12.4 (SD=3.1)Within group change at post-treatment:G1: -2.3 (calculated)G2: 0.5 (calculated)Between group change at post-treatment: -2.8 (calculated)Between group ANOVA: F=59.25, df=1,140, p<0.001Separation anxiety (range: 7-21): Pretreatment G1: 14.8 (SD=4.3)G2: 14.3 (SD=3.7)Within group change at post-treatment:G1: -2.6 (calculated)G2: -0.2 (calculated)Between group change at post-treatment: -2.4 (calculated)Between group ANOVA: F=29.24, df=1,140, p<0.001 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Berger, 20093ES-SL | UPID (range: 0-68), MeanPretreatment G1: 44.94 (SD=8.7)G2: 47.23 (SD=7.2)Within group change at post-treatment:G1: -8.73 (calculated)G2: -1.52 (calculated)Between group change at post-treatment: -7.21 (calculated)Between group ANOVA: F=53.52, df=1,164, p<0.001 | Categorical measure of probable PTSD was constructed by assessing whether reported symptoms met criteria for DSM-IV PTSD Dx, MeanProbably PTSDPretreatment G1: 28% (SD=33.3%)G2: 26% (31.7%) Within group change at post-treatment:G1: -27.3% (calculated)G2: -2.6% (calculated)Between group change at post-treatment: -24.7% (calculated)Between group chi-square: X2=14.02, df=2, p=0.001 | NA | Brief BDI (range: 0-21), Mean Pretreatment G1: 4.44 (SD=3.2)G2: 4.04 (SD=3.3)Within group change at post-treatment:G1: -1.89 (calculated)G2: -0.34 (calculated)Between group change at post-treatment: -1.55 (calculated)Between group ANOVA: F=22.55, df=1,164, p<0.001 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Berkowitz, 20114NA | UPID (range: NR) full or partial diagnosis3 Mos. followupTreatment variable OR (95% CI)): 0.268 (0.10, 0.71), p<0.01TSCC Post Traumatic Stress Index Scale (range: NR):Pretreatment G1: 53.30 (SD=1.34)G2: 51.74 (SD=1.29)Within group change at post-treatment assessment: G1: -10.33 (calculated)G2: -5.62 (calculated)Within group change at 3 Mos.: G1: -13.56 (calculated)G2: -9.52 (calculated)Between group change at post-treatment assessment: -4.71 (calculated)Between group change at 3 Mos. assessment: -4.04 (calculated)Repeated measures with mixed effect models: F=3.25, df=163, p=0.04 | NR | NA | TSCC-Dissociation Index (range: NR)Pretreatment G1: 47.64 (SD=1.12)G2: 48.23 (SD=1.07)Within group change at post-treatment assessment: G1: -5.38 (calculated)G2: -3.11 (calculated)Within group change at 3 Mos.: G1: -6.62 (calculated)G2: -4.69 (calculated)Between group change at post-treatment assessment: -2.27(calculated)Between group change at 3 Mos. assessment: -1.95 (calculated)Repeated measures with mixed effect models: F=1.28, df=163, p=0.28TSCC Anxiety Index (range: NR):Pretreatment G1: 51.34 (SD=1.33)G2: 50.45 (SD=1.29)Within group change at post-treatment assessment: G1: -10.48 (calculated)G2: -4.96 (calculated)Within group change at 3 Mos: G1: -11.70 (calculated)G2: -8.63 (calculated)Between group change at post-treatment assessment: -5.52 (calculated)Between group change at 3 Mos. assessment: -3.07 (calculated)Repeated measures with mixed effect models: F=4.89, df=163, p=0.009 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Catani, 20095NA | NA | UCLA PTSD DiagnosisPretreatment G1: 100%G2: 100%Within group change in proportion at post-treatment assessment: G1: -75%G2: -66.6%Within group change in proportion at 6 Mos.: G1: -81.3%G2: -71.4%Between group change at post-treatment assessment:8.4% (calculated)X2 difference p=NSBetween group change at 6 Mos. assessment: -9.9% X2 difference p=NS | UCLA PTSD Symptoms (range: 0-80), Pretreatment G1: 37.94 (SD=14.8)G2: 36.58 (SD=14.9)Within group change at post-treatment assessment: G1: -25.53 (calculated)G2: -23.99 (calculated)Within group change at 6 Mos.: G1: -26.63 (calculated)G2: -26.83 (calculated)Between group change at post-treatment assessment: -1.54 (calculated)Between group change at 6 Mos. assessment: 0.20 (calculated)Repeated measures ANOVA for time\*treatment interaction p=0.9 | NR |
| Ford, 20126TARGET | NA  | CAPS-CA (range: NR), B Symptoms, MeanPretreatment:G1: 19.4 (SD=9.2)G2: 13.3 (SD=3.8)Within group change at post-treatment assessment: G1: -8.7 (SD=8.6) d=1.01G2: -4.6 (SD=4.8) d=0.95Between group change at post-treatment assessment: -4.1 (SD=6.4); 95% CI (calculated) -0.22, 8.42; d=0.64CAPS-CA, C Symptoms, MeanPretreatment:G1: 22.5 (SD=8.0)G2: 18.8 (SD=5.9)Within group change at post-treatment assessment: G1: -8.5 (SD=8.2) d=1.04G2: -4.9 (SD=6.6) d=0.75 | NA | TSCC (range: NR), Anxiety. Mean Pretreatment:G1: 7.2 (SD=3.6)G2: 6.8 (SD=4.5)Within group change at post-treatment assessment: G1: -2.4 (SD=3.9) d=0.61G2: -1.3 (SD=4.7) d=0.27Between group change at post-treatment assessment: -1.2 (SD=3.6); 95% CI (calculated) -1.46, 3.66; d=0.32TSCC, Depression, Mean Pretreatment:G1: 7.4 (SD=3.7)G2: 6.9 (SD=4.1)Within group change at post-treatment assessment: G1:-2.3 (SD=3.6) d=0.65G2: -2.6 (SD=4.0) d=0.65Between group change at post-treatment assessment: 0.3 (SD=3.6); 95% CI  |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Ford, 20126TARGET (continued) |  | Between group change at post-treatment assessment: -3.5 (SD=8.4), 95% CI (calculated) -0.93, 8.13; d=0.42CAPS-CA, D Symptoms, MeanPretreatment:G1: 17.4 (SD=8.2)G2: 15.4 (SD=6.3)Within group change at post-treatment assessment: G1: -7.4 (SD=7.4) d=0.99G2: -7.4 (SD=6.1) d=1.23Between group change at post-treatment assessment: 0.02 (SD=7.5); 95% CI (calculated) -4.12, 4.12; d=0.00CAPS-CA, Total Score: MeanPretreatment:G1: 58.9 (SD=20.7)G2: 47.5 (SD=10.6)Within group change at post-treatment assessment: G1: -24.4 (SD=19.5) d=1.26G2: -17.0 (SD=12.6) d=1.35Between group change at post-treatment assessment: -7.4 (SD=14.1); 95% CI (calculated) -16.96, 2.16; d=0.53PTCI, Mean Pretreatment:G1: 108.2 (SD=32)G2: 104.6 (SD=33)Within group change at post-treatment assessment: G1: -17.9 (SD=33.6) d=0.53G2: -10.6 (SD=33.4) d=0.32Between group change at post-treatment assessment: 7.2 (SD=34.3); 95% CI (calculated) -12.79, 27.39; d=0.21 |  | (calculated) -2.56, 1.96; d=-0.10TSCC, Anger, Mean Pretreatment:G1: 8.8 (SD=7.1)G2: 8.3 (SD=6.0)Within group change at post-treatment assessment: G1: -1.0 (SD=7.4) d=0.13G2: -2.5 (SD=5.4) d=0.46Between group change at post-treatment assessment: 1.5 (SD=4.9); 95% CI (calculated) -5.46, 2.46; d=-0.30 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Gelkopf, 20097ERASE-Stress | UPID, PTSD Severity, MeanPretreatment G1: 23.6 (SD=9.3)G2: 20.4 (SD=10.3)Within group change at post-treatment:G1: -10.9 (calculated)G2: -1.9 (calculated)Between group change at post-treatment: -9.0 (calculated)Between group ANOVA: F=49.42, df=1,106, p<0.001 | UPID (range: 0-68), PTSD DiagnosisPretreatmentG1: 5.2% (calculated)G2: 0% (calculated)Within group change at post-treatment:G1: -5.2% (calculated)G2: 6.1% (calculated)Between group change at post-treatment: -11.3% (calculated) p=NR | NA | DepressionBrief BDI (range: 0-21), Mean Pretreatment G1: 3.1 (SD=2.9)G2: 2.3 (SD=2.9)Within group change at post-treatment:G1: -1.6 (calculated)G2: 0.2 (calculated)Between group change at post-treatment: -1.8 (calculated)Between group ANOVA: F=18.66, df=1,106, p<0.001 |
| Goenjian, 1997; 20058, 9NA; NA | CPTSD-RI (range: 0-80), Mean8a.Pretreatment G1: 45.3 (SD=11.0)G2: 41.1 (SD=9.0)Within group change at 1.5 years:G1: -13.1 (calculated)G2: 6.1 (calculated)Between group change at 1.5 years: -19.2 (calculated)Adjusted between group MANOVA treatment\*time: F=31.16, df=1,56, p<0.05Within group change at 3.5 years:G1: -16.3 (SD=13.0)G2: -5.4 (SD=11.0)Between group change at 3.5 years: -10.9 (calculated)Reported t-test between group difference: t=3.5, df=61, p<0.001 | NR | NA | DSRS (range: 0-63), DepressionPretreatment G1: 16.8 (SD=5.9)G2: 15.3 (SD=5.5)Within group change at 1.5 years:G1: -0.8 (calculated)G2: 4.9 (calculated)Between group change at 1.5 yearsG1 vs. G2: -5.7 (calculated)Between group difference p value not reportedWithin group change at 3.5 years:G1: -1.7 (SD=5.4)G2: 2.7 (SD=6.7)Between group change at 3.5 years: -4.4 (calculated)Reported t-test between group difference: t=2.9, df=61, p<0.01 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Jaycox, 200910SSET | NA | NA | CPSS (range: NR), Mean Pretreatment:G1: 17.46 (SD=10.37)G2: 19.41 (SD=10.00)Within group change at post-treatment assessment:G1: -3.74 (calculated), d=-0.39G2: -1.09 (calculated), d=-0.16Between group change at post-treatment assessment: -2.65 (calculated); d=-0.23; regression estimate for followup controlling for baseline=0.58, t=-1.89, p=0.058; fixed effects model adjusted for school and group leader found that estimates "remained stable" | CDI (range: NR), Mean Pretreatment: G1: 13.87 (SD=8.52)G2: 14.32 (SD=9.20)Within group change at post-treatment assessment:G1: -2.10 (calculated); d=-0.25G2: 0.60 (calculated) d=0.07Between group change at post-treatment assessment:-2.70 (calculated); d= -0.32; regression estimate of followup controlling for baseline=0.65, t=-1.99, p=0.046; fixed effects model adjusted for school and group leader found that estimates “remained stable” |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Kemp, 201011NA | NA | Meeting two or more PTSD (DSM-IV) diagnostic criteria based on systematic clinical assessment PretreatmentG1: 100%G2: 100%Within group change in proportion at post-treatment: G1: -75%G2: 0%Between group change at post-treatment:-75% (calculated)Χ2 (1, n=24)=14.40, p<0.001) | PTSD-RI symptomsPretreatment G1: 25.92 (SD=12.18)G2: 27.29 (SD=12.58)Magnitude of effect not specified by intervention type.MANCOVA controlling for group differences at pretreatment for number of DSM-IV PTSD criteria and Child PTS-RI scores F(2, 17)=9.32, p<0.01A priori contrasts identified a significant pre to post reduction in the number of DSM-IV PTSDcriteria [t(11)=4.17, p<0.01] and Child PTS-RI scores [t(11)=4.26, p=0.001] for G1 but not for G2 | STAIC – State Anxiety (range: 20-60), MeanPretreatment G1: 28.50 (SD=4.68)G2: 32.33 (SD=8.37)Within group change:G1: 0.33 (calculated)G2: -0.66 (calculated)Between group change (95% CI): 0.99 (calculated) p=NSSTAIC-Trait Anxiety (range: 20-60)Pretreatment G1: 35.42 (SD=7.51)G2: 39.58 (SD=7.23)Within group change:G1: -1.92 (calculated)G2: -3.41(calculated)Between group change (95% CI): 1.49 (calculated) p=NSCDS-Depression (range: 66-330)Pretreatment G1: 138.42 (SD=24.72)G2: 137.50 (SD=27.87)Within group change:G1: -2.67 (calculated)G2: -6.25 (calculated)Between group change (95% CI): 3.58 (calculated) p=NS  |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Layne, 200812TGCT  | NA | NR | UCLA-PTSD-RI-R (range: 0-68)Pretreatment G1: 36.37 (SD=14.27)G2: 33.02 (SD=10.27)Within group change:G1 (95% CI): -11.85 (-15.28, -8.42)G2 (95% CI): -5.67 (-8.93, -2.42)Between group difference: -6.18 (calculated)MANOVA between group time\*treatment group interaction F=6.77, df=1,125, p=0.01 | DSRS (range: 0-72)c., Pretreatment G1: 32.61 (SD=11.39)G2: 28.61 (SD=9.86)Within group change:G1 (95% CI): -2.69 (-5.33, -0.06)G2 (95% CI): 1.91 (-0.68, 4.51)Between group difference: -2.78 (calculated)MANOVA between group time\*treatment group interaction F=6.16, df=1,125, p<0.05 |
| Nugent, 201013NA | CAPS-CA (range: NR)d.No means reported.Between group differences at followup not reported. Intent-to-treat linear regression predicting PTSD symptoms at post-treatment, adjusted for sex, age, and prior trauma PTSD severity, showed treatment group OR (95% CI)=1.32 (0.84, 2.08) (calculated) | CAPS-CAd. DiagnosisNo data reported for PTSD diagnosis other than X2<1; p=NS for G1 vs. G2 at post-treatment | NA | NR |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Robbe, 201014NA | NA | NR | UCLA PTSD-RI-R (range: 0-68)Pretreatment G1: 43.8 (SD=8.5)G2: 42.1 (SD=8.8)Within group LS mean change LOCF:G1: -20.4 (SD=2.1)G2: -22.8 (SD=2.1)Between group LS mean change score difference LOCF 95% CI: -7.6, 2.9, p=0.373CSDC, parent-rated (range: 0-30)Pretreatment G1: 33.5 (SD=10.5)G2: 34.1 (SD=10.4)Within group LS mean change LOCF:G1: -12.4 (SD=1.7)G2: -17.3 (SD=1.9)Between group LS mean change score difference LOCF 95% CI: -9.1, -0.6, p=0.025CGI-S, clinician-rated (range: 0-7)Pretreatment G1: 4.5 (SD=0.6)G2: 4.4 (SD=0.6)Within group LS mean change LOCF:G1: -1.4 (SD=0.2)G2: -1.8 (SD=0.2)Between group LS mean change score difference LOCF 95% CI: -0.8, 0.0, p=0.031CGI-I, clinician-rated symptom improvement (range: 0-7)Pretreatment G1: NAG2: NAWithin group LS mean change LOCF:G1: 2.4 (SD=0.2)G2: 2.2 (SD=0.2)Between group LS mean change score difference LOCF 95% CI: -0.6, 0.3, p=0.415 | CDRS-R (range: 0-17), MeanPretreatment G1: 40.3 (SD=14.4)G2: 41.2 (SD=14.2)Within group LS mean change LOCF:G1: -10.0 (SD=1.5)G2: -12.3 (SD=1.6)Between group LS mean change score difference LOCF 95% CI: -6.0,1.3, p=0.210 |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Robertf, 199915NA | NA | ASD symptom respondersG1: 83%G2: 38%Between-group difference in relieving ASD symptoms, X²=5.24, df=1, p=0.04 | NR | NR |
| Robertg, 200816NA | NA | ASD Checklist% responders at post-treatment:G1: 60.0%G2: 72.2%G3: 54.5%Between group difference in % responders at post-treatment p=NS | ASD Checklist, MeanPretreatmentG1: 42.6 (SD=12.4)G2: 47.6 (SD=15.0)G3: 44.6 (SD=14.0)Within group % change in mean score post-treatmentG1: -62.6% (SD 39.5)G2: -73.6% (SD 40.4)G3: -65.1% (SD 41.5)Between group difference in % change in mean score post-treatment: p=NS | NR |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Salloumh., 200817NA | NA | NR | UPID-PTSD Symptoms (range: 0-80)Pretreatment G1: 28.28 (SD=13.61)G2: 31.32 (SD=12.43) Post-treatmentG1: 44.03 (SD=13.03)G2: 42.32 (SD=9.58)Within group change at post-treatment assessment: G1: -15.75 (calculated)G2: -11.00 (calculated)Within group change in proportion at 20 day followup: G1: -21.60 (calculated)G2: -20.47 (calculated)Between group change at post-treatment assessment:-4.75 (calculated)Intent-to-treat analyses effect size: 0.95Between group change at 6 Mos. assessment: -1.13 (calculated) Intent-to-treat analyses effect size: 1.34General linear modeling repeated measure procedure time\*treatment interaction p=NS | MFQ-C, MeanPretreatment G1: 25.48 (SD=9.17)G2: 23.41 (SD=9.58)Within group change at post-treatment assessment: G1: -8.57 (calculated)G2: -2.95 (calculated)Within group change in proportion at 20 day followup: G1: -12.48 (calculated)G2: -9.18 (calculated)Between group change at post-treatment assessment: -5.62 (calculated)Intent-to-treat analyses effect size: 0.47Between group change at 6 Mos. assessment: -3.30 (calculated) Intent-to-treat analyses effect size: 0.92General linear modeling repeated measure procedure time\*treatment interaction p=NS |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Salloum, 201218 NA | NA | UCLA PTSD-I of 38+ (clinically significant PTSD)Pretreatment:G1: 46.2%G2: 39.4%Within group change at 12 Mos. assessment:G1: -40.3%G2: -29.4%Between group change at 12 Mos. assessment: -10.9%, p=NR | UCLA-PTSD-I (range: NR)Pretreatment:G1: 46.82 (SD=13.00)G2: 42.80 (SD=10.77)Within group change at post-treatment assessment: G1: -15.64, d=0.92, p=NRG2: -15.23, d=0.78, p=NRBetween group change at post-treatment assessment: -0.41, p=NRWithin group change at 3 Mos. assessment: G1: -16.94, d=1.06, p=NRG2: -16.5, d=0.78, p=NRBetween group change at 3 Mos. assessment: -0.44, p=NRWithin group change at 12 Mos. assessment: G1: -22.08, d=1.83, p=NR; (RCI: 70.59% improved, 2.94% deteriorated)G2: -17.27, d=1.50, p=NR (RCI: 60% improved, 3.33% deteriorated)Between group change at 12 Mos. assessment: -4.81, ANOVA time\*treatment interaction p=NS; RCI difference p=NS | MFQ-C of 29+ (clinically significant depression) Pretreatment:G1: 43.6%G2: 27.3%Within group change at 12 Mos. assessment:G1: -43.6%G2: -20.8%Between group change at 12 Mos. assessment: -22.8%, p=NR MFQ-C (range: NR)Pretreatment:G1: 27.62 (SD=10.18)G2: 22.83 (SD=8.65)Within group change at post-treatment assessment: G1: -9.12, d=0.91, p=NRG2: -9.00, d=0.99, p=NRBetween group change at post-treatment assessment: -0.12, p=NRWithin group change at 3 Mos. assessment: G1: -9.18, d=0.87, p=NRG2: -8.00, d=0.85, p=NRBetween group change at 3 Mos. assessment: -1.18, p=NRWithin group change at 12 Mos. assessment:G1: -13.94, d=1.43, p=NR (RCI: 52.9% improved, 0% deteriorated)G2: -9.00, d=0.97, p=NR (RCI: 43.33% improved, 3.33% deteriorated)Between group change at 12 Mos. assessment: -4.94, ANOVA time\*treatment interaction p=NR; RCI difference p=NSEGI (range: NR)Pretreatment:G1: 53.03 (SD=17.75)G2: 46.00 (SD=21.83) |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Salloum, 201218 NA |  |  |  | Within group change at post-treatment assessment: G1: -16.90, d=0.92, p=NR G2: -16.69, d=0.78, p=NRBetween group change at post-treatment assessment: -0.39, p=NRWithin group change at 3 Mos. assessment: G1: -19.62, d=0.96, p=NRG2: -16.62, d=1.18, p=NRBetween group change at 3 Mos. assessment: -3.00, p=NRWithin group change at 12 Mos. assessment:G1: -26.72, d=1.61, p=NR (RCI: 68.75% improved, 0% deteriorated)G2: -19.00, d=0.91, p=NR (RCI: 55.17% improved, 3.45% deteriorated)Between group change at 12 Mos. assessment: -7.72, ANOVA time\*treatment interaction p=NR; RCI difference p=NSGD (range: NR)Pretreatment:G1: 2.71 (SD=1.32)G2: 2.72 (SD=1.13)Within group change at post-treatment assessment: G1: -0.80, d=0.60, p=NRG2: -1.03, d=0.86, p=NRBetween group change at post-treatment assessment: 0.23, p=NRWithin group change at 3 Mos. assessment: G1: -1.36, d=1.06, p=NRG2: -1.34, d=0.78, p=NRBetween group change at 3 Mos. assessment: -0.02, p=NRWithin group change at 12 Mos. assessment:G1: -1.53, d=1.19, p=NRG2: -1.24, d=1.06, p=NRBetween group change at 12 Mos. assessment: -0.29, ANOVA time\*treatment interaction p=NR |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Smith, 200719NA | NA | ADIS-C/P PTSD Diagnosis (range: NR)Pretreatment G1: 100%G2: 100%Within group change in proportions at post-treatment:G1: -92%G2: -42%Between group change in proportions at post-treatment: -50% (calculated)X²=6.8, df=1, 24, p<0.01  | CPSS Symptoms (range: NR)Pretreatment G1: 28.1 (SD=8.8)G2: 28.3 (SD=10.5)Within group change at post-treatment:G1: -25.1 (calculated)G2: -3.05 (calculated)Between group change at post-treatment: -22.05 (calculated)MANCOVA F=48.3, df=1,18, p<0.001 C-RIES Symptoms (range: NR)Pretreatment G1: 47.5 (SD=11.5)G2: 41.6 (SD=11.7)Within group change at post-treatment:G1: -39.0 (calculated)G2: -6.3 (calculated)Between group change at post-treatment: -32.7 (calculated) MANCOVA F=36.8, df=1,18, p<0.001 CAPS symptoms (range: NR)Pretreatment G1: 60.9 (SD=9.6)G2: 54.7 (SD=14.6)Within group change at post-treatment:G1: -48.9 (calculated)G2: -14.4 (calculated)Between group change at post-treatment: -34.5 (calculated) MANCOVA F=20.2, df=1,18, p<0.005 | DSRS Depression (range: NR)Pretreatment G1: 18.3 (SD=5.2)G2: 13.9 (SD=5.6)Within group change at post-treatment:G1: -10.3 (calculated)G2: -0.6 (calculated)Between group change at post-treatment: -9.7 (calculated) MANCOVA F=19.1, df=1,18, p<0.001 RCMAS Anxiety (range: NR)Pretreatment G1: 19.8 (SD=5.6)G2: 16.3 (SD=5.7)Within group change at post-treatment:G1: -12.4 (calculated)G2: 0.2 (calculated)Between group change at post-treatment: -12.6 (calculated) MANCOVA F=14.3, df=1,18, p<0.005  |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Stein, 200320NA | NA | NA | CPSS symptoms (range: 0-51)Pretreatment G1: 24.5 (6.8)G2: 23.5 (7.2)Within group change:G1: -15.6 (calculated)G2: -8.0 (calculated)Adjusted between group change (95% CI): -7.0 (-10.8, -3.2) | CDI Depression (range: 0-52)DifferencePretreatment G1: 17.6 (10.8)G2: 16.7 (7.3)Within group change:G1: -8.2 (calculated)G2: -4.0 (calculated)Adjusted between group change (95% CI): -3.4 (-6.5, -0.4) |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Tol, 2008; 201021, 22NA; NA |  NA | NR | CPSS (range: 0-68)Pretreatment G1: 20.92 (SD=8.75)G2: 22.35 (SD=8.39)Within group change at 1 week:G1: -9.10 (SD=9.20)G2: -4.85 (SD=9.49)Within group change at 6 Mos.:G1: -10.35 (SD=8.89)G2: -6.15 (SD=10.04)Between group difference at 1 week (95% CI): d=0.55 (0.35, 0.75)Between group difference at 6 Mos.: Mixed method regression analysis mean change difference adjusted for school mean (95% CI): 2.78 (1.02, 4.53), d=0.44 (0.24, 0.64) | DSRS depression (range: 0-36)Pretreatment G1: 12.29 (SD=3.33)G2: 12.55 (SD=3.47)Within group change at 1 week:G1: -0.80 (SD=3.88)G2: 0.50 (SD=4.33)Within group change at 6 Mos.:G1: -0.82 (SD=3.82)G2: 0.16 (SD=4.73)Between group difference at 1 week (95% CI): d=0.31 (0.12, 0.51)Between group difference at 6 Mos.: Mixed method regression analysis mean change difference adjusted for school mean (95% CI): -0.70 (-0.08, 1.49), d= 0.24 (0.04, 0.43)SCARED-5 anxiety (range: 0-10)Pretreatment G1: 4.38 (SD=1.76)G2: 4.46 (SD=1.87)Within group change at 1 week:G1: -0.97 (SD=2.16)G2: -0.65 (SD=2.32)Within group change at 6 Mos.:G1: -1.06 (SD=2.45)G2: -0.96 (SD=2.49)Between group difference at 1 week (95% CI): d=0.14 (-0.05, 0.34)Between group difference at 6 Mos.: Mixed method regression analysis mean change difference adjusted for school mean (95% CI): -0.12 (-0.31, 0.56), d=0.04 (-0.16, 0.24) |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Tol, 201223 NA | NA | NA | CPSS (range: 0-51), PTSD symptoms:Pretreatment G1: 15.03 (SD=8.89)G2: 15.70 (SD=9.12)Within group change at post-treatment assessment:G1: NRG2: NRBetween group change at post-treatment assessment: NRLGCM estimate (SE): 0.281 (0.332); p=NS | DSRS (range: 0-36), Depressive symptoms:Pretreatment G1: 8.39 (SD=4.54)G2: 8.56 (SD=4.37)Within group change at post-treatment assessment:G1: NRG2: NRBetween group change at post-treatment assessment: NRLGCM estimate (SE): 0.115 (0.112); p=NSSCARED-5 (range 0-10), Anxiety symptoms:Pretreatment G1: 3.29 (SD=2.13)G2: 3.17 (SD=2.16)Within group change at post-treatment assessment:G1: NRG2: NRBetween group change at post-treatment assessment: NRLGCM estimate (SE): -0.037 (0.065); p=NSSDQ (range: 0-40), Psychological difficulties:Pretreatment G1: 10.74 (SD=5.57)G2: 10.29 (SD=5.44)Within group change at post-treatment assessment:G1: NRG2: NRBetween group change at post-treatment assessment: NRLGCM estimate (SE): -0.198 (0.280); p=NS |

Evidence Table 5. Benefits (KQ 1 & 2) (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year, Trial Name  | Prevention of Traumatic Stress Symptoms or Syndromes  | Remission of PTSD  | Reduction in Severity or Number of Traumatic Stress Syndromes or Symptoms | Prevention of Reduction in Mental Health Conditions or Symptoms  |
| Tol, 201223NA |  |  |  | Supernatural complaints (range: 0-18):Pretreatment G1: 2.21 (SD=2.59)G2: 1.97 (SD=1.92)Within group change at post-treatment assessment:G1: NRG2: NRBetween group change at post-treatment assessment: NRLGCM estimate (SE): -0.121 (0.064); p<0.06 |
| Zehnder, 201024NA | IBS-K (range: NR), MeanPretreatment:G1: 29.3 (SD=23.7)G2: 26.3 (SD=23.0)Within group change at Time 1 assessment:G1: -7.7 (calculated)G2: -7.8 (calculated)Between group change at Time 1 assessment: 0.1 (calculated)Within group change at Time 2 assessment:G1: -5.7 (calculated)G2: -4.4; (calculated)Between group change at Time 2 assessment: -1.3 (calculated)Repeated measures ANOVA treatment\*time interaction: F=0.10, p=NS | NA  | NA  | DIKJ (range: NR), MeanPretreatment:G1: 10.1 (SD=6.0)G2: 9.6 (SD=6.5)Within group change at Time 1 assessment:G1: -1.9 (calculated)G2: -1.0 (calculated)Between group change at Time 1 assessment: -0.9 (calculated) Within group change at Time 2 assessment:G1: -1.0 (calculated)G2: -0.9 (calculated)Between group change at Time 2 assessment -0.1 (calculated)Repeated measures ANOVA treatment\*time interaction: F=0.01, p=NS |

a. 18 month data reported in #840 differs slightly from that reported in #1589.

b. Post-Tx results and mean change only reported in figure.

c. Also conducted 4 month follow-up on PTSD, Depression, and Grief Reactions. These analyses were only done on those who had pre, post, and 4-month follow-up data (not ITT analysis).

d. Girls receiving propranolol reported more PTSD symptoms relative to girls receiving placebo. Boys receiving propranolol showed a nonsignificant trend toward fewer PTSD symptoms than boys receiving placebo.

e. Sertraline did not demonstrate efficacy compared with placebo.

f. No standardized scales used.

g. Placebo was statistically as effective as either Imipramine or Fluoxetine in treating symptoms of ASD.

h. Treatment satisfaction 1: "I learned more about grief and trauma reactions" (1-10, with 10 being highest); mean score at follow-up: 9.20. Treatment satisfaction 2: "I expressed my thoughts and feelings about what happened"; mean score at follow-up: 9.18. Treatment satisfaction 3: "On a scale from 1 to 10, how helpful was counseling for you?"; mean score at follow-up: 9.31.

i. Debriefing was no more effective than placebo group intervention, although both groups made significant improvements in PTSD symptoms.

Abbreviations: ADIS-C/P = Anxiety Disorders Interview Schedule; ASD = Acute Stress Disorder; BDI = Beck Depression Inventory; CAPS-CA = Clinician-Administered Post-Traumatic Stress Disorder Scale For Children And Adolescents; CDI = Child Depression Inventory; CDRS-R = Children’s Depression Rating Scale-Revised; CDS = Children’s Depression Scale; CGI-I = Clinical Global Impressions-Improvement Scale; CGI-S = Clinical Global Impressions – Severity Scale; CI = confidence interval; CPSS = Child PTSD Symptom Scale; CPTSD-RI = Child Post-Traumatic Stress Reaction Index; C-RIES = Children’s Revised Impact of Event Scale; CSDC = Child Stress Disorder Checklist; d = effect size; df = degrees of freedom; DIKJ = German Version of CDI; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DSRS = Depression Self-Rating Scale; Dx = diagnosis; EGI = Extended Grief Inventory; ERASE-Stress – Enhancing Resilience among Students Experiencing Stress; ES-SL = ERASE Stress Sri Lanka; G = group; GD = Global Distress; IBS-K = German Version of CAPS-CA; IES = Impact of Events Scale; LGCM = latent growth curve modeling; LOCF = last observation carried forward; LS = least-squares; MFQ-C = Mood and Feeling Questionnaire – Child Version; Mos. = months; N = number; NA = not applicable; NR = not reported; NS = not significant; OR = odds ratio; PSS-SR = Post-Traumatic Stress Disorder Symptom Scale Self Report; PTCI = Post-Traumatic Cognitions Inventory; PTSD = Posttraumatic Stress Disorder; RCI = Reliable Change Index; RCMAS = Revised Children’s Manifest Anxiety Scale; SCARED = Screen for Child Anxiety Related Emotional Disorders; SCARED-5 = Self-Report for Anxiety-Related Disorders; SD = standard deviation; SDQ = Strengths and Difficulties Questionnaire; SE = standard error; SSET = Support for Students Exposed to Trauma; STAIC – State Trait Anxiety Inventory for Children; TARGET = Trauma Affect Regulation: Guide for Education and Therapy; TGCT = Trauma and Grief Component Therapy; TSCC = Trauma Symptom Checklist for Children; UCLA PTSD-I = University of California, Los Angeles Post-Traumatic Stress Disorder Index; UCLA-PTSD-RI-R = University of California, Los Angeles Post-Traumatic Stress Disorder Reaction Index, Revised; UCLA PTSD-Symptom Severity = University of California, Los Angeles Post-Traumatic Stress Disorder – Symptom Severity; UPID = University of California, Los Angeles Index for DSM-IV for children.